- Why are the majority of Monkeypox infected people who have sex with men (MSM)?
- Experimental treatment improves skin cancer survival by 25%
- People who get flu vaccine are 40% less likely to develop Alzheimer’s disease
- Depriving women of the right to abortion is a setback for medical health and society
- 83 U.S. attorneys general pledge not to prosecute women who have abortions
- Genomic data reveal evolutionary trajectory of current monkeypox epidemic
The clinical progress of stem cell treatment of childhood diseases
The clinical progress of stem cell treatment of childhood diseases. In recent years, stem cell treatment of childhood diseases has received much attention worldwide. Because children’s immune systems are not as strong as young people, they are very susceptible to viruses in the external environment. Therefore, it is particularly important to find a better and safer method to treat childhood diseases.
Mesenchymal stem cell therapy represents a potentially revolutionary treatment method, which has been widely used in the treatment and research process of a variety of pediatric diseases. It has been shown in clinical trials of pediatric lung, heart, orthopedics, endocrine, neurological and hematological diseases. Has a huge therapeutic potential.
Mesenchymal stem cells for treatment of graft-versus-host disease in children
Mesenchymal stem cells have been successfully used to treat graft-versus-host disease. Mesenchymal stem cell drugs for graft-versus-host disease have been launched internationally, and China has also entered the stage of clinical trials. Some mesenchymal stem cells for this disease The new stem cell drug has received clinical approval.
Graft versus host disease is a disease with very complex clinical manifestations, affecting the functions of various organs including skin, gastrointestinal tract, liver, kidney, bones, joints, muscles and lungs. Traditional treatments include immunosuppressants, such as high-dose steroid hormones and cyclosporine, but many patients do not respond or become dependent on these treatments, and there are many adverse side effects. The cure rate of mesenchymal stem cell therapy in children with steroid-resistant acute graft-versus-host disease is as high as 73%.
Mesenchymal stem cells for treatment of spinal muscular atrophy in children
Spinal muscular atrophy is a progressive neurodegenerative disease, and currently there is no good clinical treatment. A clinical study reported that three children with spinal muscular atrophy were treated with allogeneic bone marrow mesenchymal stem cells, which significantly improved muscle strength, facial expressions, ventilatory breathing ability, and speaking ability. It is also believed that the mechanism by which mesenchymal stem cells exert their therapeutic effects may be permanent, rather than therapeutically repairing.
Mesenchymal stem cells for treatment of bronchopulmonary dysplasia in children
Bronchopulmonary dysplasia affects the health of up to 50% of newborns and is the most common long-term lung disease in premature infants. Severe bronchopulmonary dysplasia is closely related to neurodevelopmental disorders, pulmonary hypertension, and pulmonary heart disease. In a dose-escalation study, it was found that very preterm infants born at 27 weeks of gestation or earlier were given mesenchymal stem cell therapy at 5 to 14 days old. Compared with infants receiving ordinary treatment, infants who received mesenchymal stem cell treatment had a lower degree of bronchopulmonary dysplasia and a lower level of inflammation.
Mesenchymal stem cells in the treatment of children with cerebral palsy
Cerebral palsy is mainly manifested as central dyskinesia and abnormal posture. It can also be accompanied by mental retardation, epilepsy, perceptual disturbance, language impairment and mental behavior abnormalities. It is one of the main diseases that cause motor disabilities in children.
The most common cause is premature birth, which causes up to 15% of newborns to have cerebral palsy. A review of 47 cases found that mesenchymal stem cell therapy is the safest and most effective no matter whether it is intracapsular or intravenous administration. After treatment with mesenchymal stem cells, the child’s obvious and appreciable manifestations, such as fever, vomiting, and cramps, disappeared on their own within 72 hours.
In China, in 2017, the project “Clinical Research on Umbilical Cord Mesenchymal Stem Cells/Neural Stem Cells for Treatment of Children with Cerebral Palsy”, which was filed by the Health and Family Planning Commission, has been officially launched, aiming to establish stem cell transplantation as the core, integrating medical care, nursing care, and A standardized program integrating rehabilitation and psychology can prolong the survival time of children, improve their quality of life, and reduce the burden on the family and society.
Mesenchymal stem cells treat childhood autism
The underlying pathology of autism spectrum disorders, such as immune system disorders, cerebral hypoperfusion and inflammation, can be used as targets for mesenchymal stem cell therapy.
In a clinical trial of mesenchymal stem cells in the treatment of autism, 37 children with autism received allogeneic mesenchymal stem cell therapy. After 24 weeks of treatment, it was evaluated by the Child Autism Score Scale, Clinical Overall Impression Scale and Abnormal Behavior Checklist.
It was found that children who received mesenchymal stem cell therapy compared with children who did not receive mesenchymal stem cell therapy The severity of symptoms in children with autism is significantly reduced.
Children are the hope of the motherland, the future of the nation, and the health of children are related to the progress of society, the prosperity of the nation and the happiness of a family. In recent years, children’s health problems have attracted more and more attention from the general public. In particular, the application of stem cells in children’s diseases has become more and more common. Stem cells have been used to treat children’s diseases globally.
(sourceinternet, reference only)